A carregar...
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
The standard treatment for Triple Negative Breast Cancer (TNBC) patients is cytotoxic chemotherapy, but it is restricted since the duration of response is usually short. Blocking the PD-1/PD-L1 pathway through monoclonal antibodies (mAbs) appears to be a promising therapeutic strategy for TNBC patie...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6159755/ https://ncbi.nlm.nih.gov/pubmed/30294328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.02140 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|